Evidence map›Paper›PMID 34478523›Full record

ArticleBlood advances2021

A novel mechanism of thrombocytopenia by PS exposure through TMEM16F in sphingomyelin synthase 1 deficiency.

Yoritaka Fujii, Makoto Taniguchi, Shingo Nagaya, Yoshibumi Ueda, Chieko Hashizume, Ken Watanabe, Hiroyuki Takeya, Takeo Kosaka, Toshiro Okazaki

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. TMEM16 proteins: CaInternational journal of molecular medicine · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Yoritaka FujiiDepartment of General and Digestive Surgery, Faculty of Medicine.
Makoto TaniguchiDepartment of Life Science, Medical Research Institute, and.ORCID 0000-0001-5920-8285
Shingo NagayaDepartment of Hematology and Immunology, Faculty of Medicine, Kanazawa Medical University, Kahoku, Japan.
Yoshibumi UedaDepartment of Hematology and Immunology, Faculty of Medicine, Kanazawa Medical University, Kahoku, Japan.
Chieko HashizumeDepartment of General and Digestive Surgery, Faculty of Medicine.ORCID 0000-0002-5937-3915
Ken WatanabeDepartment of Bone and Joint Disease, National Center for Geriatrics and Gerontology, Aichi, Japan.
Hiroyuki TakeyaDepartment of Applied Life Science, Sojo University, Kumamoto, Japan; and.
Takeo KosakaDepartment of General and Digestive Surgery, Faculty of Medicine.
Toshiro OkazakiDepartment of Hematology and Immunology, Faculty of Medicine, Kanazawa Medical University, Kahoku, Japan.
Kanazawa Medical University · JPNational Center for Geriatrics and Gerontology · JPObayashi (Japan) · JPSojo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sphingomyelin synthase 1 (SMS1) contributes to the generation of membrane sphingomyelin (SM) and affects SM-mediated physiological functions. Here, we describe the hematologic phenotypes, such as reduced circulating platelets and dysfunctional hemostasis, in SMS1-deficient (SMS1-KO) mice. SMS1-KO mice display pathologic manifestations related to idiopathic thrombocytopenia (ITP), including relatively high amounts of peripheral blood reticulated platelets, enhanced megakaryopoiesis in the bone marrow and spleen, and splenomegaly. Deficiency of SMS1, but not SMS2, prevented SM production and enhanced phosphatidylserine (PS) externalization on the plasma membranes of platelets and megakaryocytes. Consequently, SMS1-KO platelets were excessively cleared by macrophages in the spleen. Multimer formation in the plasma membrane of TMEM16F, a known calcium (Ca2+)-activated nonselective ion channel and Ca2+-dependent PS scramblase, was enhanced; the result was PS externalization to outer leaflets through increased Ca2+ influx in immortalized mouse embryonic fibroblasts established from SMS1-KO mice (SMS1-KO tMEFs), as seen with SMS1-KO platelets. Thus, SMS1 deficiency changed the TMEM16F distribution on the membrane microdomain, regulating Ca2+ influx-dependent PS exposure. SMS1-KO tMEFs in which TMEM16F was knocked out by using the CRISPR/Cas9 system lacked both the Ca2+ influx and excess PS exposure seen in SMS1-KO tMEFs. Therefore, SM depletion on platelet membrane microdomains due to SMS1 deficiency enhanced PS externalization via a Ca2+ influx through TMEM16F activation, leading to elevated platelet clearance and causing hemostasis dysfunction through thrombocytopenia. Our current findings show that the SM-rich microdomain generated by SMS1 is a potent regulator of thrombocytopenia through TMEM16F, suggesting that its dysfunction may be a novel additional mechanism of ITP.

Indexed as

PhosphatidylserinesThrombocytopeniaAnimalsAnoctaminsFibroblastsMiceTransferases (Other Substituted Phosphate Groups)Anoctaminsphosphatidylcholine-ceramide phosphocholine transferasePhosphatidylserinesTransferases (Other Substituted Phosphate Groups)

Identifiers

PMID34478523
PMCPMC8945624
OpenAlexW3196483729

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.